Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Tianyu Pharmaceutical Co Ltd
Depreciation & Amortization
Zhejiang Tianyu Pharmaceutical Co Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SZSE:300702
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Depreciation & Amortization
-¥147.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-12%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Depreciation & Amortization
-¥199.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-21%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Depreciation & Amortization
-¥58.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Zhejiang Tianyu Pharmaceutical Co Ltd
Glance View
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. The company is headquartered in Taizhou, Zhejiang and currently employs 4,991 full-time employees. The company went IPO on 2017-09-19. The firm operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The firm also operates Other segment. The firm sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.
